Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 11 Nov 2016 |
| Genmab’s 2016 Capital Markets Day | 10 Nov 2016 |
| Genmab Announces Phase III Study of Daratumumab in Combination with Carfilzomib in Multiple Myeloma | 10 Nov 2016 |
| CHMP Issues Positive Opinion Recommending Arzerra® (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL | 10 Nov 2016 |
| Articles of Association for Genmab A/S | 10 Nov 2016 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 9 Nov 2016 |